Other formats:
BibTeX
LaTeX
RIS
@misc{838412,
author = {Guzi, Timothy and Paruch, Kamil and Dwyer, Michael and Doll, Ronald and Girijavallabhan, Viyyoor and Mallams, Alan and Alvarez, Carmen and Keertikar, Kartik and Rivera, Jocelyn and Chan, TinandYau and Madison, Vincent and Fischmann, Thierry and Dillard, Lawrence and Tran, Vinh and He, Zhen and James, Ray and Park, Haengsoon and Paradkar, Vidyadhar and Hobbs, Douglas},
keywords = {cyclin dependent kinase; inhibitor; cancer},
language = {eng},
title = {Pyrazolopyrimidines as Cyclin Dependent Kinase Inhibitors},
year = {2004}
}
TY - PAT
ID - 838412
AU - Guzi, Timothy - Paruch, Kamil - Dwyer, Michael - Doll, Ronald - Girijavallabhan, Viyyoor - Mallams, Alan - Alvarez, Carmen - Keertikar, Kartik - Rivera, Jocelyn - Chan, Tin-Yau - Madison, Vincent - Fischmann, Thierry - Dillard, Lawrence - Tran, Vinh - He, Zhen - James, Ray - Park, Haengsoon - Paradkar, Vidyadhar - Hobbs, Douglas
PY - 2004
TI - Pyrazolopyrimidines as Cyclin Dependent Kinase Inhibitors
KW - cyclin dependent kinase
KW - inhibitor
KW - cancer
N2 - The title pyrazolo[1,5-a]pyrimidines [I R = H, alkyl, cycloalkyl, etc.; R2 = alkyl, halo, aryl, etc.; R3 = H, halo, aryl, etc.; R4 = H, halo, alkyl], useful as inhibitors of cyclin dependent kinases for treatment, prevention, inhibition, or amelioration of one or more diseases assocd. with the CDKs such as cancer, were prepd. Thus, reacting II (prepn. given) with 4-aminomethylpyridine afforded 93% III which showed IC50 of 0.020 .mu.M and 0.029 .mu.M against CDK2 kinase (cyclin A or cyclin E-dependent). The pharmaceutical compn. comprising the compd. I is claimed.
ER -
GUZI, Timothy, Kamil PARUCH, Michael DWYER, Ronald DOLL, Viyyoor GIRIJAVALLABHAN, Alan MALLAMS, Carmen ALVAREZ, Kartik KEERTIKAR, Jocelyn RIVERA, Tin-Yau CHAN, Vincent MADISON, Thierry FISCHMANN, Lawrence DILLARD, Vinh TRAN, Zhen HE, Ray JAMES, Haengsoon PARK, Vidyadhar PARADKAR and Douglas HOBBS. \textit{Pyrazolopyrimidines as Cyclin Dependent Kinase Inhibitors}. 2004.
|
